Trial Profile

An Open-label, Multiple-Ascending Dose, Two-Part Dose Ranging and Cohort Expansion Study of INI-4001 in Patients With Advanced Solid Tumours

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 25 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INI 4001 (Primary) ; Atezolizumab; Avelumab; Cemiplimab; Durvalumab; Nivolumab; Pembrolizumab
Indications Solid tumours
Focus Adverse reactions
Sponsors Inimmune

Most Recent Events

24 Jul 2024 According to Inimmune media release , this trial is expected to be complete by the end of 2025.
24 Jul 2024 According to Inimmune media release, company announced the dosing of the first patient
24 Jul 2024 According to Inimmune media release Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com